SGLT2 Hesitance; Furosemide’s Indication Grows; Legal Fight Over Entresto Generic

From 2022 to 2023, uptake of SGLT2 inhibitors was low in patients with a class Ia recommendation. (Journal of the American College of Cardiology)

In a phase IIa study, the oral controlled metabolic accelerator drug HU6 resulted in weight loss for patients with obesity-related heart failure with preserved ejection fraction, according to Rivus Pharmaceuticals.

Plant and animal fats were linked to opposite trends in cardiovascular disease mortality in a prospective cohort study. (JAMA Internal Medicine)

Mounting evidence suggests that dietary and gut microbe-derived metabolites are associated with a higher risk for heart failure. (Circulation: Heart Failure)

Furosemide (Furoscix) was granted an indication expansion to treat congestion in adults with New York Heart Association class IV symptoms, scPharmaceuticals announced.

A federal court declined to block the launch of a generic competitor to Novartis’ sacubitril/valsartan (Entresto), though more litigation is pending. (Reuters)

For patients with cardiogenic shock, immediate extracorporeal membrane oxygenation failed to improve outcomes by 1 year, but patients with advanced hemodynamic compromise seemed to benefit from it in the ECMO-CS trial. (European Journal of Heart Failure)

Cardiac MRI-derived pulmonary capillary wedge pressure was a predictor of incident heart failure and cardiovascular events. (ESC Heart Failure)

Patients who underwent percutaneous left atrial appendage occlusion had better outcomes if they received 3 months of low-dose direct oral anticoagulants rather than dual antiplatelet therapy, according to the small ADALA trial. (JAMA Cardiology)

For survivors of a cancer-associated cryptogenic stroke, the choice of apixaban (Eliquis) or aspirin apparently made no difference in subsequent event risk. (JAMA Neurology)

Pulse Biosciences announced that its nanosecond pulsed field ablation technology, developed to treat atrial fibrillation during cardiac surgery, was successful in initial human cases.

Z-drugs for insomnia were generally not linked to cardiovascular harm, but benzodiazepines were. (European Journal of Preventive Cardiology)

The Sansa wearable patch was given FDA 510(k) clearance for simultaneous detection of sleep apnea and ECG recording, maker Huxley Medical said.

Pregnant women with obstructive sleep apnea had a reduced risk of gestational hypertension and preeclampsia if they used continuous positive airway pressure treatment. (JAMA Network Open)

The link between polycystic ovary syndrome and cardiovascular risk was supported by a meta-analysis. (Journal of the American Heart Association)

Researchers reported developing a proteomic age clock that predicts an individual’s risk of major chronic diseases and premature death. (Nature Medicine)

The AORTA Gene score was validated to help identify ascending aortic dilation and adverse thoracic aortic events. (European Heart Journal)